Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai To Market Aricept At More "Affordable Prices" In China, Larger Asia

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Eisai has begun selling its flagship drug, Aricept, for Alzheimer's disease treatment at "affordable prices" in China and several other Asian countries, a company spokesman said

You may also be interested in...



Astellas Looks Up In 2010; Eisai Draws Growth From Domestic And Chinese Markets: Japanese Pharma Earnings Roundup (Part 1 Of 2)

Major Japanese pharmas face many of the same problems as major Western pharmas, including patent cliffs and growth slowdown in traditional markets. Japanese pharmas, on the other hand, have been slower to establish themselves in emerging markets. But that may soon be changing, as can be seen in this Japanese pharma earnings roundup, a periodic feature in PharmAsia News.

Astellas Looks Up In 2010; Eisai Draws Growth From Domestic And Chinese Markets: Japanese Pharma Earnings Roundup (Part 1 Of 2)

Major Japanese pharmas face many of the same problems as major Western pharmas, including patent cliffs and growth slowdown in traditional markets. Japanese pharmas, on the other hand, have been slower to establish themselves in emerging markets. But that may soon be changing, as can be seen in this Japanese pharma earnings roundup, a periodic feature in PharmAsia News.

Eisai Seeks Global Approval For Cancer Agent Eribulin As Aricept Patent Expiration Looms Near

TOKYO - Eisai March 31 said it had applied for manufacturing and marketing approval with Japan's Ministry of Health, Labor and Welfare; U.S. FDA and the European Medicines Agency for eribulin for the treatment of locally advanced and metastatic breast cancer

Related Content

UsernamePublicRestriction

Register

SC074577

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel